Advanced search
Publication Cover
Clinical Interventions in Aging Volume 7, 2012 - Issue
Submit an article Journal homepage
171
Views
6
CrossRef citations to date
0
Altmetric
Review

Gabapentin for once-daily treatment of post-herpetic neuralgia: a review

Benjamin Beal1 Division of Pain Medicine, Department of Anesthesiology, University of California, San Diego, CA, USA
,
Tobias Moeller-Bertram1 Division of Pain Medicine, Department of Anesthesiology, University of California, San Diego, CA, USA;2 VA San Diego Healthcare System, San Diego, CA, USA
,
Jan M Schilling1 Division of Pain Medicine, Department of Anesthesiology, University of California, San Diego, CA, USA
&
Mark S Wallace1 Division of Pain Medicine, Department of Anesthesiology, University of California, San Diego, CA, USACorrespondence[email protected]
Pages 249-255 | Published online: 12 Jul 2012

Figures & data

Figure 1 Rate of herpes zoster and post herpetic neuralgia with increasing age.

Adapted from Harpaz 2008, with permission Depomed (Menlo Park, CA, USA).

Note: *Per 1,000 person-years.
Figure 1 Rate of herpes zoster and post herpetic neuralgia with increasing age.Adapted from Harpaz 2008, with permission Depomed (Menlo Park, CA, USA).

Table 1 Comparison of adverse events with gabapentin extendedrelease 1800 mg versus placebo

Figure 2 Mean change in average daily pain score (by week, and baseline observation carried forward analysis). Adapted from Sang et al.Citation17

Figure 2 Mean change in average daily pain score (by week, and baseline observation carried forward analysis). Adapted from Sang et al.Citation17

Figure 3 Patient global impression of change at endpoint: intent-to-treat population. Adapted from Sang et al.Citation17

Figure 3 Patient global impression of change at endpoint: intent-to-treat population. Adapted from Sang et al.Citation17

Figure 4 Percentage of safety population reporting dizziness and somnolence for all patients (overall) and the subgroup of patients aged ≥65 years.

Adapted from Sweeney et al.Citation25

Figure 4 Percentage of safety population reporting dizziness and somnolence for all patients (overall) and the subgroup of patients aged ≥65 years.Adapted from Sweeney et al.Citation25

Figure 5 Least squares mean from baseline to endpoint (using baseline observation carried forward) in average daily pain scores and treatment differences for all patients (overall) and in patients aged ≥65 years.

Adapted from Sweeney et al.Citation25

Note: *P < 0.05.
Figure 5 Least squares mean from baseline to endpoint (using baseline observation carried forward) in average daily pain scores and treatment differences for all patients (overall) and in patients aged ≥65 years.Adapted from Sweeney et al.Citation25

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.